These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

414 related items for PubMed ID: 27170423

  • 1. Late presentation of generalised bullous pemphigoid-like reaction in a patient treated with pembrolizumab for metastatic melanoma.
    Parakh S, Nguyen R, Opie JM, Andrews MC.
    Australas J Dermatol; 2017 Aug; 58(3):e109-e112. PubMed ID: 27170423
    [Abstract] [Full Text] [Related]

  • 2. Lupus-like cutaneous reaction following pembrolizumab: An immune-related adverse event associated with anti-PD-1 therapy.
    Shao K, McGettigan S, Elenitsas R, Chu EY.
    J Cutan Pathol; 2018 Jan; 45(1):74-77. PubMed ID: 29028121
    [Abstract] [Full Text] [Related]

  • 3. Disproportionality analysis of bullous pemphigoid adverse events with PD-1 inhibitors in the FDA adverse event reporting system.
    Aggarwal P.
    Expert Opin Drug Saf; 2019 Jul; 18(7):623-633. PubMed ID: 31088310
    [Abstract] [Full Text] [Related]

  • 4. Bullous pemphigoid in elderly woman affected by non-small cell lung cancer treated with pembrolizumab: A case report and review of literature.
    Cosimati A, Rossi L, Didona D, Forcella C, Didona B.
    J Oncol Pharm Pract; 2021 Apr; 27(3):727-733. PubMed ID: 32772795
    [Abstract] [Full Text] [Related]

  • 5. Cutaneous autoimmune effects in the setting of therapeutic immune checkpoint inhibition for metastatic melanoma.
    Mochel MC, Ming ME, Imadojemu S, Gangadhar TC, Schuchter LM, Elenitsas R, Payne AS, Chu EY.
    J Cutan Pathol; 2016 Sep; 43(9):787-91. PubMed ID: 27161449
    [Abstract] [Full Text] [Related]

  • 6. Timing of Onset of Adverse Cutaneous Reactions Associated With Programmed Cell Death Protein 1 Inhibitor Therapy.
    Wang LL, Patel G, Chiesa-Fuxench ZC, McGettigan S, Schuchter L, Mitchell TC, Ming ME, Chu EY.
    JAMA Dermatol; 2018 Sep 01; 154(9):1057-1061. PubMed ID: 30027278
    [Abstract] [Full Text] [Related]

  • 7. Bullous pemphigoid induced by pembrolizumab in a patient with advanced melanoma expressing collagen XVII.
    Wada N, Uchi H, Furue M.
    J Dermatol; 2017 Oct 01; 44(10):e240-e241. PubMed ID: 28677843
    [No Abstract] [Full Text] [Related]

  • 8. A case of bullous pemphigoid in a patient with metastatic melanoma treated with pembrolizumab.
    Carlos G, Anforth R, Chou S, Clements A, Fernandez-Peñas P.
    Melanoma Res; 2015 Jun 01; 25(3):265-8. PubMed ID: 25831416
    [Abstract] [Full Text] [Related]

  • 9. Severe bullous pemphigoid associated with pembrolizumab therapy for metastatic melanoma with complete regression.
    Rofe O, Bar-Sela G, Keidar Z, Sezin T, Sadik CD, Bergman R.
    Clin Exp Dermatol; 2017 Apr 01; 42(3):309-312. PubMed ID: 28211077
    [Abstract] [Full Text] [Related]

  • 10. Two cases of anti-programmed cell death 1-associated bullous pemphigoid-like disease and eruptive keratoacanthomas featuring combined histopathology.
    Bandino JP, Perry DM, Clarke CE, Marchell RM, Elston DM.
    J Eur Acad Dermatol Venereol; 2017 Aug 01; 31(8):e378-e380. PubMed ID: 28222231
    [No Abstract] [Full Text] [Related]

  • 11. Bullous disorders associated with anti-PD-1 and anti-PD-L1 therapy: A retrospective analysis evaluating the clinical and histopathologic features, frequency, and impact on cancer therapy.
    Siegel J, Totonchy M, Damsky W, Berk-Krauss J, Castiglione F, Sznol M, Petrylak DP, Fischbach N, Goldberg SB, Decker RH, Stamatouli AM, Hafez N, Glusac EJ, Tomayko MM, Leventhal JS.
    J Am Acad Dermatol; 2018 Dec 01; 79(6):1081-1088. PubMed ID: 30025829
    [Abstract] [Full Text] [Related]

  • 12. Delayed skin toxicity associated with pembrolizumab therapy for metastatic melanoma.
    Arianayagam S, Ieremia E, Matin RN.
    Eur J Dermatol; 2019 Jun 01; 29(3):349-351. PubMed ID: 31389799
    [No Abstract] [Full Text] [Related]

  • 13. Severe bullous pemphigoid in a metastatic lung cancer patient treated with pembrolizumab.
    Adachi E, Honda T, Nonoyama S, Irie H, Yamamura K, Otsuka A, Kabashima K.
    J Dermatol; 2019 Jul 01; 46(7):e232-e233. PubMed ID: 30758879
    [No Abstract] [Full Text] [Related]

  • 14. Case Report: A Rare Case of Pembrolizumab-Induced Bullous Pemphigoid.
    Zhang X, Sui D, Wang D, Zhang L, Wang R.
    Front Immunol; 2021 Jul 01; 12():731774. PubMed ID: 34594337
    [Abstract] [Full Text] [Related]

  • 15. Cutaneous metastases at the sites of pembrolizumab-induced bullous pemphigoid lesions in a patient with melanoma.
    Ványai B, Chien YC, Beke L, Szabó IL, Péter Z, Steuer-Hajdu K, Várvölgyi T, Méhes G, Emri G.
    Immunotherapy; 2022 Dec 01; 14(17):1377-1382. PubMed ID: 36475303
    [Abstract] [Full Text] [Related]

  • 16. Granulomatous Tumoral Melanosis Associated With Pembrolizumab Therapy: A Mimicker of Disease Progression in Metastatic Melanoma.
    Woodbeck R, Metelitsa AI, Naert KA.
    Am J Dermatopathol; 2018 Jul 01; 40(7):523-526. PubMed ID: 29924748
    [Abstract] [Full Text] [Related]

  • 17. Cutaneous lupus associated with pembrolizumab therapy for advanced melanoma: a report of three cases.
    Blakeway EA, Elshimy N, Muinonen-Martin A, Marples M, Mathew B, Mitra A.
    Melanoma Res; 2019 Jun 01; 29(3):338-341. PubMed ID: 30762712
    [Abstract] [Full Text] [Related]

  • 18. [Grover's-like drug eruption under anti-PD-1 therapy for metastatic melanoma].
    Amini-Adle M, Balme B, Dalle S.
    Ann Dermatol Venereol; 2018 Dec 01; 145(12):802-803. PubMed ID: 30415933
    [No Abstract] [Full Text] [Related]

  • 19. Lymphocytic gastritis induced by pembrolizumab in a patient with metastatic melanoma.
    Yip RHL, Lee LH, Schaeffer DF, Horst BA, Yang HM.
    Melanoma Res; 2018 Dec 01; 28(6):645-647. PubMed ID: 30256271
    [Abstract] [Full Text] [Related]

  • 20. A Severe, Refractory Case of Mucous Membrane Pemphigoid After Treatment With Pembrolizumab: Brief Communication.
    Bezinelli LM, Eduardo FP, Migliorati CA, Ferreira MH, Taranto P, Sales DB, Santi CG, Macarenco RS, Godoy CPV, Corrêa L, Buzaid AC.
    J Immunother; 2019 Dec 01; 42(9):359-362. PubMed ID: 31246641
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 21.